PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Shows the trajectory of a company's cash-generation capacity. Consistent growth in operating and free cash flow suggests a robust, self-funding business model—crucial for value investors seeking undervalued, cash-rich opportunities.
18.43%
Net income growth at 75-90% of GNPX's 21.43%. Bill Ackman would call for strategic or operational tweaks to match competitor’s earnings growth.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-43.55%
Negative yoy SBC while GNPX is 214.41%. Joel Greenblatt would see less immediate dilution advantage if talent levels remain strong.
69.28%
Slight usage while GNPX is negative at -623.06%. John Neff would note competitor possibly capturing more free cash unless expansions are needed here.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
100.00%
A yoy AP increase while GNPX is negative at -325.80%. John Neff would see competitor possibly improving relationships or liquidity more rapidly.
-92.45%
Negative yoy usage while GNPX is 2.50%. Joel Greenblatt would see a short-term advantage in freeing up capital unless competitor invests effectively in these lines.
109.32%
Well above GNPX's 50.65%. Michael Burry would worry about large intangible write-downs or revaluation gains overshadowing real performance.
22.94%
Operating cash flow growth similar to GNPX's 22.29%. Walter Schloss would see parallel improvements or market conditions in cash generation.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-1.52%
We cut debt repayment yoy while GNPX is 0.00%. Joel Greenblatt sees competitor possibly lowering risk more if expansions do not hamper them.
1850.82%
We slightly raise equity while GNPX is negative at -90.02%. John Neff sees competitor possibly preserving share count or buying back shares.
No Data
No Data available this quarter, please select a different quarter.